FREMONT, Calif., Aug. 23, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genomic analysis systems, announced today that it intends to file its Quarterly Report on Form 10-Q for the period ended June 30, 2011 within two weeks. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission relating to its Form 10-Q filing.
In order to complete its financial statements and other information contained in the Quarterly Report on Form 10-Q, the company needs additional time to finalize the valuation amounts and related accounting treatment of convertible preferred stock, convertible notes and warrants issued on May 27, 2011 in the company's $30.6 million private placement financing.
About WaferGen Biosystems, Inc.
WaferGen Biosystems, Inc. develops, manufactures and sells state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries to advance next generation sequencing and ultimately personalized medicine. WaferGen offers the breakthrough SmartChip Real-Time PCR System, a next-generation Real-Time PCR system for discovery and validation of gene expression patterns (biomarkers) on a single platform. For additional information, please see http://www.wafergen.com.
Forward Looking Statements
This press release contains certain "forward-looking statements" relating to the expected filing date of the company's Form 10-Q for the second quarter of 2011. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about t
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved